| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 192.84 M USD | 48.80 M USD | -13.03 M USD | -45.82 M USD | -28.86 M USD | -30.27 M USD | -32.29 M USD | -25.98 M USD |
| Depreciation & Amortization | 27.18 M USD | 19.76 M USD | 8.18 M USD | 3.48 M USD | 1.82 M USD | 1.58 M USD | 1.22 M USD | 769000 USD |
| Stock-Based Compensation | 36.86 M USD | 33.22 M USD | 19.79 M USD | 10.32 M USD | 6.88 M USD | 2.41 M USD | 854000 USD | 144000 USD |
| Capital Expenditures | 59.25 M USD | 129.74 M USD | 151.85 M USD | 11.91 M USD | 3.52 M USD | 455000 USD | 165000 USD | 418000 USD |
| Cash Flow from Investing | -59.25 M USD | -129.30 M USD | -193.95 M USD | 54.51 M USD | 29.27 M USD | -41.60 M USD | -60.50 M USD | 12.31 M USD |
| Cash Flow from Financing | 16.86 M USD | 22.87 M USD | 400.42 M USD | 167.93 M USD | 1.39 M USD | 75.55 M USD | 92.72 M USD | 22.06 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — |
| Free Cash Flow | 133.59 M USD | -80.94 M USD | -164.88 M USD | -57.72 M USD | -32.38 M USD | -30.72 M USD | -32.45 M USD | -26.40 M USD |
TransMedics Group Inc. is a commercial-stage medical technology company focused on advancing organ transplant therapy for patients with end-stage organ failure. It develops and commercializes the Organ Care System (OCS), a portable platform that preserves, optimizes, and monitors donor organs in near-physiologic conditions outside the body, overcoming limitations of traditional cold storage methods. The OCS supports multiple organ types, enabling improved transplant outcomes through real-time assessment and maintenance during transport. TransMedics Group Inc. operates in the health technology sector, specifically medical specialties, serving transplant centers and healthcare providers to expand access to viable organs. The company enhances organ utilization rates and logistics, including aviation partnerships for nationwide transport networks. Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics Group Inc. plays a critical role in transforming solid organ transplantation by integrating innovative perfusion technology with comprehensive organ recovery services.